ApiFix completed a Series B equity financing. The company is pursuing 2019 FDA clearance and subsequent U.S. launch of MID-C for the treatment of scoliosis in young patients.
Minimally Invasive Deformity Correction (MID-C) is a posterior dynamic deformity correction system that supports curve correction while retaining spine flexibility. The removable system acts as an internal brace and employs a patented unidirectional, self-adjusting rod mechanism and motion-preserving polyaxial joints, allowing additional post-operative correction over time.
Palm Tree IV, a new U.S.-based investor, led the round with participation from existing shareholders.
ApiFix completed a Series B equity financing. The company is pursuing 2019 FDA clearance and subsequent U.S. launch of MID-C for the treatment of scoliosis in young patients.
Minimally Invasive Deformity Correction (MID-C) is a posterior dynamic deformity correction system that supports curve correction while retaining spine flexibility. The...
ApiFix completed a Series B equity financing. The company is pursuing 2019 FDA clearance and subsequent U.S. launch of MID-C for the treatment of scoliosis in young patients.
Minimally Invasive Deformity Correction (MID-C) is a posterior dynamic deformity correction system that supports curve correction while retaining spine flexibility. The removable system acts as an internal brace and employs a patented unidirectional, self-adjusting rod mechanism and motion-preserving polyaxial joints, allowing additional post-operative correction over time.
Palm Tree IV, a new U.S.-based investor, led the round with participation from existing shareholders.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
